Diaceutics PLC
("Diaceutics" or the "Company")
Sale of Shares and PDMR Shareholding
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces that on 12 May 2021, Jordan Clark, the Chief Commercial Officer of Diaceutics, sold 50,000 ordinary shares of £0.002 each in the Company ("Ordinary Shares") at a price of 124.5 pence per Ordinary Share. As a result of the sale, Jordan's shareholding is 855,190 Ordinary Shares, representing approximately 1.02% of the Company's issued share capital.
Enquiries:
| Diaceutics PLC | |||
| Peter Keeling, Chief Executive Officer | via Alma PR | ||
| Philip White, Chief Financial Officer |
| ||
|
|
| ||
| Cenkos Securities plc (Nominated adviser and broker) | +44 (0)207 397 8900 | ||
| Callum Davidson / Giles Balleny |
| ||
| Michael Johnson (Sales) |
| ||
|
|
| ||
| Alma PR | Tel: +44 (0)20 3405 0205 or diaceutics@almapr.co.uk | ||
| Caroline Forde |
| ||
| Robyn Fisher |
| ||
| Kieran Breheny |
|
|
|
About Diaceutics
At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - our Proprietary Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics. The Company, listed on the AIM Market of the London Stock Exchange, has created commercially useful data sets for every precision medicine that has come to market. We have built the world's largest repository of diagnostic testing data with a growing network of 2,500 laboratories in 51 countries. www.diaceutics.com
About DXRX - The Diagnostic Network®
DXRX is Diaceutics' proprietary diagnostic network for precision medicine. DXRX is an end-to-end solution for the development and commercialisation of Precision Medicine diagnostics. The platform enables a vibrant marketplace where all stakeholders in Precision Medicine come to find trusted partners and collaborations in a secure, standardised way. DXRX provides access to a pipeline of global diagnostic testing data on one secure platform.
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a. | Name | Jordan Clark | |||||
| 2 | Reason for notification |
| |||||
| a. | Position/Status | Chief Commercial Officer | |||||
| b. | Initial notification/ Amendment | Initial | |||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
| a. | Name | Diaceutics PLC | |||||
| b. | LEI | 213800VEWQBB39ZB8J81 | |||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
| a. | Description of the financial instrument, type of instrument | Ordinary shares of £0.002 each
ISIN: GB00BJQTGV64 | |||||
| b. | Nature of the transaction | Sale of Ordinary Shares | |||||
| c. | Price(s) and volume(s) |
|
|
|
|
| |
|
| Price(s) | Volume(s) |
| ||||
| 124.5 p | 50,000 |
| |||||
|
| |||||||
| e. | Date of the transaction | 12 May 2021 | |||||
| f. | Place of the transaction | AIM Market of the London Stock Exchange | |||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
